Gyre Therapeutics to Present Positive Phase 3 Trial Results of Hydronidone for Liver Fibrosis in Chronic Hepatitis B at AASLD 2025

Reuters10-14

<a href="https://laohu8.com/S/GYRE">Gyre Therapeutics</a> to Present Positive Phase 3 Trial Results of Hydronidone for Liver Fibrosis in Chronic Hepatitis B at AASLD 2025

Gyre Therapeutics Inc. announced that it will present results from its positive Phase 3 clinical trial evaluating Hydronidone, a novel anti-fibrotic agent, for the treatment of liver fibrosis in chronic hepatitis B. The results will be presented at The Liver Meeting® 2025, organized by the American Association for the Study of Liver Diseases (AASLD), which is scheduled to be held from November 7-10, 2025, in Washington D.C. The study abstract, titled "Phase 3 Trial of Hydronidone for Liver Fibrosis in Chronic Hepatitis B," has been selected as a Poster of Distinction and will be presented by Prof. Lungen Lu of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544930-en) on October 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2575329146?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-14 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575329146","market":"us","top_or_hot":-1,"title":"Gyre Therapeutics to Present Positive Phase 3 Trial Results of Hydronidone for Liver Fibrosis in Chronic Hepatitis B at AASLD 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/GYRE\">Gyre Therapeutics</a> to Present Positive Phase 3 Trial Results of Hydronidone for Liver Fibrosis in Chronic Hepatitis B at AASLD 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Gyre <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced that it will present results from its positive Phase 3 clinical trial evaluating Hydronidone, a novel anti-fibrotic agent, for the treatment of liver fibrosis in chronic hepatitis B. The results will be presented at The Liver Meeting® 2025, organized by the American Association for the Study of Liver Diseases (AASLD), which is scheduled to be held from November 7-10, 2025, in Washington D.C. The study abstract, titled \"Phase 3 Trial of Hydronidone for Liver Fibrosis in Chronic Hepatitis B,\" has been selected as a Poster of Distinction and will be presented by Prof. Lungen Lu of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544930-en) on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gyre Therapeutics to Present Positive Phase 3 Trial Results of Hydronidone for Liver Fibrosis in Chronic Hepatitis B at AASLD 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGyre Therapeutics to Present Positive Phase 3 Trial Results of Hydronidone for Liver Fibrosis in Chronic Hepatitis B at AASLD 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-14 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/GYRE\">Gyre Therapeutics</a> to Present Positive Phase 3 Trial Results of Hydronidone for Liver Fibrosis in Chronic Hepatitis B at AASLD 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Gyre <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced that it will present results from its positive Phase 3 clinical trial evaluating Hydronidone, a novel anti-fibrotic agent, for the treatment of liver fibrosis in chronic hepatitis B. The results will be presented at The Liver Meeting® 2025, organized by the American Association for the Study of Liver Diseases (AASLD), which is scheduled to be held from November 7-10, 2025, in Washington D.C. The study abstract, titled \"Phase 3 Trial of Hydronidone for Liver Fibrosis in Chronic Hepatitis B,\" has been selected as a Poster of Distinction and will be presented by Prof. Lungen Lu of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544930-en) on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"纳斯达克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL9m44YZ:1","article_id":"2575329146","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575329146","pubTimestamp":1760439619,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Gyre Therapeutics to Present Positive Phase 3 Trial Results of Hydronidone for Liver Fibrosis in Chronic Hepatitis B at AASLD 2025. Gyre Therapeutics Inc. announced that it will present results from its positive Phase 3 clinical trial evaluating Hydronidone, a novel anti-fibrotic agent, for the treatment of liver fibrosis in chronic hepatitis B. The results will be presented at The Liver Meeting 2025, organized by the American Association for the Study of Liver Diseases , which is scheduled to be held from November 7-10, 2025, in Washington D.C. The study abstract, titled \"Phase 3 Trial of Hydronidone for Liver Fibrosis in Chronic Hepatitis B,\" has been selected as a Poster of Distinction and will be presented by Prof. Lungen Lu of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gener","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","BK4585":"ETF&股票定投概念","BK4139":"生物科技","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4112":"金融交易所和数据","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","GYRE":"Gyre Therapeutics","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD"},"translate_title":"Gyre Therapeutics将在2025年AASLD上展示水氢尼酮治疗慢性乙型肝炎肝纤维化的积极3期试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GYRE":0.9,"NDAQ":0.9},"content_text":"Gyre Therapeutics to Present Positive Phase 3 Trial Results of Hydronidone for Liver Fibrosis in Chronic Hepatitis B at AASLD 2025\n    \n\n        Gyre Therapeutics Inc. announced that it will present results from its positive Phase 3 clinical trial evaluating Hydronidone, a novel anti-fibrotic agent, for the treatment of liver fibrosis in chronic hepatitis B. The results will be presented at The Liver Meeting® 2025, organized by the American Association for the Study of Liver Diseases (AASLD), which is scheduled to be held from November 7-10, 2025, in Washington D.C. The study abstract, titled \"Phase 3 Trial of Hydronidone for Liver Fibrosis in Chronic Hepatitis B,\" has been selected as a Poster of Distinction and will be presented by Prof. Lungen Lu of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544930-en) on October 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2575329146","isCrawlerRequest":true}